Wenyue Hu
YOU?
Author Swipe
View article: Systematic evaluation of porcine platelet lysate as a fetal bovine serum substitute: enhancing cell proliferation, maintaining differentiation potential, and ensuring immunophenotypic stability
Systematic evaluation of porcine platelet lysate as a fetal bovine serum substitute: enhancing cell proliferation, maintaining differentiation potential, and ensuring immunophenotypic stability Open
pPL effectively supports the in vitro expansion of various cells, helps maintain the immunophenotypic stability of MSCs, and shows superiority in osteogenic differentiation. With its unique "proliferation-first, differentiation-controllabl…
View article: Moxibustion modulates gut microbiota and improves bone marrow hematopoiesis in mice with myelosuppression-induced aplastic anemia
Moxibustion modulates gut microbiota and improves bone marrow hematopoiesis in mice with myelosuppression-induced aplastic anemia Open
Objective: To observe the effects of moxibustion on the hematopoietic function in mice with aplastic anemia (AA) induced by bone marrow (BM) suppression, and to investigate the intervention effects of moxibustion on AA from the perspective…
View article: β‐Lactam Adjunctive Therapy Compared to Vancomycin or Daptomycin Monotherapy in Adult Patients With Methicillin‐Resistant <i>Staphylococcus aureus</i> Bacteremia: An Update Systematic Review, Meta‐Analysis, and Trial Sequential Analysis
β‐Lactam Adjunctive Therapy Compared to Vancomycin or Daptomycin Monotherapy in Adult Patients With Methicillin‐Resistant <i>Staphylococcus aureus</i> Bacteremia: An Update Systematic Review, Meta‐Analysis, and Trial Sequential Analysis Open
Background: This study evaluated the efficacy and safety of vancomycin (VAN) or daptomycin (DAP) combined with β‐lactams (BLs) versus monotherapy (STAN) for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Methods: PubMed, We…
View article: Topical hADSCs-HA Gel Promotes Skin Regeneration and Angiogenesis in Pressure Ulcers by Paracrine Activating PPARβ/δ Pathway
Topical hADSCs-HA Gel Promotes Skin Regeneration and Angiogenesis in Pressure Ulcers by Paracrine Activating PPARβ/δ Pathway Open
Our research showed that topical application of hADSCs-HA gel played an important role in dermal regeneration and angiogenesis. Therefore, hADSCs-HA gel exhibited the potential as a novel stem-cell-based therapeutic strategy of treating pr…
View article: Integration of single-cell sequencing with machine learning and Mendelian randomization analysis identifies the NAP1L1 gene as a predictive biomarker for Alzheimer's disease
Integration of single-cell sequencing with machine learning and Mendelian randomization analysis identifies the NAP1L1 gene as a predictive biomarker for Alzheimer's disease Open
Background The most effective approach to managing Alzheimer's disease (AD) lies in identifying reliable biomarkers for AD to forecast the disease in advance, followed by timely early intervention for patients. Methods Transcriptomic data …
View article: Translation of nonclinical to clinical safety findings for 27 biotherapeutics
Translation of nonclinical to clinical safety findings for 27 biotherapeutics Open
Human adverse drug reactions (ADRs), and in vivo nonclinical adverse and nonadverse findings, were identified in 27 biotherapeutic programs and placed into organ categories to determine translation. The sensitivity of detecting human ADRs …
View article: Adaptive class augmented prototype network for few-shot relation extraction
Adaptive class augmented prototype network for few-shot relation extraction Open
Relation extraction is one of the most essential tasks of knowledge construction, but it depends on a large amount of annotated data corpus. Few-shot relation extraction is proposed as a new paradigm, which is designed to learn new relatio…
View article: Use of the dTAG system <i>in vivo</i> to degrade CDK2 and CDK5 in adult mice and explore potential safety liabilities
Use of the dTAG system <i>in vivo</i> to degrade CDK2 and CDK5 in adult mice and explore potential safety liabilities Open
The degradation tag (dTAG) system for target protein degradation can remove proteins from biological systems without the drawbacks of some genetic methods, such as slow kinetics, lack of reversibility, low specificity, and the inability to…
View article: Data from Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Data from Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance Open
Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biological perspective but drug development is often hindered by toxicities and inadequate efficacy. Predicting drug behaviors using cellular and animal…
View article: Data from Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Data from Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance Open
Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biological perspective but drug development is often hindered by toxicities and inadequate efficacy. Predicting drug behaviors using cellular and animal…
View article: Data from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901
Data from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901 Open
Clinical trials of selective RAF inhibitors in patients with melanoma tumors harboring activated BRAFV600E have produced very promising results, and a RAF inhibitor has been approved for treatment of advanced melanoma. However, about a thi…
View article: Supplemental Methods from Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Supplemental Methods from Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance Open
Detailed description of the methods used in the manuscript
View article: Supplemental Table 1 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 1 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S1 shows plasma exposure in humans or rats.
View article: Supplemental Table 1 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 1 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S1 shows plasma exposure in humans or rats.
View article: Supplemental Table 4 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 4 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S4 shows expression change in solute carrier family genes.
View article: Supplementary Figure 1 from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901
Supplementary Figure 1 from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901 Open
PDF file, 39K, Relationship between oral doses and average plasma concentrations of PD-0325901 in athymic nu/nu mice.
View article: Supplemental Table 3 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 3 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S3 shows A: Most significantly impacted pathways. B: Most significantly impacted upstream regulators.
View article: Supplementary Figure 1 from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901
Supplementary Figure 1 from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901 Open
PDF file, 39K, Relationship between oral doses and average plasma concentrations of PD-0325901 in athymic nu/nu mice.
View article: Supplemental Table 4 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 4 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S4 shows expression change in solute carrier family genes.
View article: Supplementary Figure 2 from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901
Supplementary Figure 2 from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901 Open
PDF file, 75K, Body weight changes in nude mice administered RAF inhibitor (PF-04880594) are maintained in mice co-treated with MEK inhibitor (PD-0325901).
View article: Supplemental Table 2 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 2 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S2 shows IC50 values for CDK4/6 inhibitors in human and rat bone marrow.
View article: Supplemental Tables S1-S9 from Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Supplemental Tables S1-S9 from Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance Open
Table S1. Statistics for the crystallographic analysis; Table S2. Biochemical and cellular potencies of the second generation CDK-directed drug AG-024322; Table S3. In vitro analysis of binding potency of abemaciclib, dinaciclib, and palbo…
View article: Supplemental Figure 2 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Figure 2 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Figure S2 shows A) significantly perturbed genes, B) Venn diagram of changed genes, C) hierarchical clustering of changed genes, D) volcano plot of all genes.
View article: Supplemental Figure 1 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Figure 1 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Figure S1 shows duodenum stained with PAS/Alcian blue, and TEM from jejunum.
View article: Data from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901
Data from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901 Open
Clinical trials of selective RAF inhibitors in patients with melanoma tumors harboring activated BRAFV600E have produced very promising results, and a RAF inhibitor has been approved for treatment of advanced melanoma. However, about a thi…
View article: Supplemental Figure 1 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Figure 1 and legend from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Figure S1 shows duodenum stained with PAS/Alcian blue, and TEM from jejunum.
View article: Supplementary Figure 3 from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901
Supplementary Figure 3 from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901 Open
PDF file, 141K, Photographs of canine muzzles showing skin flushing following PF-04880594 treatment.
View article: Data from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Data from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Recently three different cyclin-dependent kinase 4 and 6 (CDK4/6) dual inhibitors were approved for the treatment of breast cancer (palbociclib, ribociclib, and abemaciclib), all of which offer comparable therapeutic benefits. Their safety…
View article: Supplemental Table 3 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Supplemental Table 3 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology Open
Table S3 shows A: Most significantly impacted pathways. B: Most significantly impacted upstream regulators.